Published in J Virol on January 01, 1999
Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol (2007) 3.04
Mouse hepatitis coronavirus A59 nucleocapsid protein is a type I interferon antagonist. J Virol (2006) 1.53
Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host Microbe (2012) 1.39
Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer. J Virol (2009) 1.21
Diverse functions of RNase L and implications in pathology. Biochimie (2007) 1.21
The 2'-5' oligoadenylate/RNase L/RNase L inhibitor pathway regulates both MyoD mRNA stability and muscle cell differentiation. Mol Cell Biol (2000) 1.14
Functional analysis of the ATP-binding cassette (ABC) transporter gene family of Tribolium castaneum. BMC Genomics (2013) 1.11
The biased nucleotide composition of the HIV genome: a constant factor in a highly variable virus. Retrovirology (2012) 1.10
Conservation of a stepwise, energy-sensitive pathway involving HP68 for assembly of primate lentivirus capsids in cells. J Virol (2004) 1.08
Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2',5'-oligoadenylate synthetase from prostate cancer cells. Nucleic Acids Res (2006) 1.07
Murine coronavirus induces type I interferon in oligodendrocytes through recognition by RIG-I and MDA5. J Virol (2010) 1.07
Inhibition of HIV type 1 replication in CD4+ and CD14+ cells purified from HIV type 1-infected individuals by the 2-5A agonist immunomodulator, 2-5A(N6B). AIDS Res Hum Retroviruses (2007) 0.99
ICP0 prevents RNase L-independent rRNA cleavage in herpes simplex virus type 1-infected cells. J Virol (2006) 0.94
A plant orthologue of RNase L inhibitor (RLI) is induced in plants showing RNA interference. J Mol Evol (2004) 0.94
Identification of novel host cell binding partners of Oas1b, the protein conferring resistance to flavivirus-induced disease in mice. J Virol (2012) 0.89
Evidence for a different susceptibility of primate lentiviruses to type I interferons. J Virol (2012) 0.87
Uterine epithelial cells specifically induce interferon-stimulated genes in response to polyinosinic-polycytidylic acid independently of estradiol. PLoS One (2012) 0.87
Anti-human immunodeficiency virus activity of tau interferon in human macrophages: involvement of cellular factors and beta-chemokines. J Virol (2003) 0.86
Pathologic effects of RNase-L dysregulation in immunity and proliferative control. Front Biosci (Schol Ed) (2012) 0.83
Can't RIDD off viruses. Front Microbiol (2014) 0.83
Varicella-zoster virus does not significantly induce cell defence mechanism mediated by the 2-5A/RNase L pathway during its replication cycle. Med Microbiol Immunol (2005) 0.79
Recent Insights into HIV Accessory Proteins. Curr Infect Dis Rep (2003) 0.78
The Roles of RNase-L in Antimicrobial Immunity and the Cytoskeleton-Associated Innate Response. Int J Mol Sci (2016) 0.76
Previously Unidentified Single Nucleotide Polymorphisms in HIV/AIDS Cases Associate with Clinical Parameters and Disease Progression. Biomed Res Int (2016) 0.75
ABCE1 is essential for S phase progression in human cells. Cell Cycle (2016) 0.75
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
A method for isolation of intact, translationally active ribonucleic acid. DNA (1983) 13.67
pppA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc Natl Acad Sci U S A (1978) 5.69
Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. Cell (1993) 4.10
An absolute method for protein determination based on difference in absorbance at 235 and 280 nm. Anal Biochem (1980) 3.42
Interferon action: RNA cleavage pattern of a (2'-5')oligoadenylate--dependent endonuclease. Science (1981) 2.38
A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J (1993) 2.28
2-5A-dependent RNase molecules dimerize during activation by 2-5A. J Biol Chem (1995) 2.27
Constitutive expression of (2'-5') oligo A synthetase confers resistance to picornavirus infection. Nature (1988) 2.18
Resistance of vaccinia virus to interferon is related to an interference phenomenon between the virus and the interferon system. Virology (1984) 2.04
Radioimmune, radiobinding and HPLC analysis of 2-5A and related oligonucleotides from intact cells. Nature (1980) 2.03
Natural occurrence of 2-5A in interferon-treated EMC virus-infected L cells. Nature (1979) 2.01
Synthesis of (2'-5')oligoadenylate and activation of an endoribonuclease in interferon-treated HeLa cells infected with reovirus. J Virol (1982) 1.77
Vaccinia virus E3L protein is an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme. Virology (1998) 1.73
Cloning and characterization of a RNAse L inhibitor. A new component of the interferon-regulated 2-5A pathway. J Biol Chem (1995) 1.60
Constitutive expression of a 2',5'-oligoadenylate synthetase cDNA results in increased antiviral activity and growth suppression. J Interferon Res (1989) 1.45
Activation of the ppp(A2'p)nA system in interferon-treated, herpes simplex virus-infected cells and evidence for novel inhibitors of the ppp(A2'p)nA-dependent RNase. Eur J Biochem (1984) 1.45
A full-length murine 2-5A synthetase cDNA transfected in NIH-3T3 cells impairs EMCV but not VSV replication. Virology (1990) 1.38
2-5A accumulates to high levels in interferon-treated, vaccinia virus-infected cells in the absence of any inhibition of virus replication. J Virol (1984) 1.29
Protective activity of tetracycline analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells. Res Virol (1990) 1.04
Regulation of human immunodeficiency virus replication by 2',5'-oligoadenylate-dependent RNase L. J Virol (1998) 1.02
Activation of ribonuclease L by (2'-5')(A)4-poly(L-lysine) conjugates in intact cells. Biochemistry (1986) 1.00
Analogue inhibitor of 2-5A action: effect on the interferon-mediated inhibition of encephalomyocarditis virus replication. EMBO J (1985) 0.99
Protection of HeLa-T4+ cells against human immunodeficiency virus (HIV) infection after stable transfection with HIV LTR-2',5'-oligoadenylate synthetase hybrid gene. FASEB J (1990) 0.98
Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Lancet (1987) 0.96
Modulation of nuclear matrix-associated 2',5'-oligoadenylate metabolism and ribonuclease L activity in H9 cells by human immunodeficiency virus. J Biol Chem (1989) 0.95
RNase L inhibitor (RLI) antisense constructions block partially the down regulation of the 2-5A/RNase L pathway in encephalomyocarditis-virus-(EMCV)-infected cells. Eur J Biochem (1998) 0.91
(2'-5')Oligoadenylate and intracellular immunity against retrovirus infection. Int J Biochem (1992) 0.89
HIV-1 reverse transcriptase: inhibition by 2',5'-oligoadenylates. Biochemistry (1993) 0.88
Characterization of two murine (2'-5')(A)n-dependent endonucleases of different molecular mass. Eur J Biochem (1989) 0.85
Alteration of nuclear (2'-5')oligoriboadenylate synthetase and nuclease activities preceding replication of human immunodeficiency virus in H9 cells. Biol Chem Hoppe Seyler (1988) 0.85
2',5'-Oligoadenylate-dependent RNase L is a dimer of regulatory and catalytic subunits. J Biol Chem (1993) 0.81
Diagnostic value of the determination of an interferon-induced enzyme activity: decreased 2',5'-oligoadenylate dependent binding protein activity in AIDS patient lymphocytes. AIDS Res (1986) 0.80
Mode of action of the anti-AIDS compound poly(I).poly(C12U) (Ampligen): activator of 2',5'-oligoadenylate synthetase and double-stranded RNA-dependent kinase. J Interferon Res (1993) 0.78
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem (1997) 6.52
A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med (2000) 3.54
Interferon, double-stranded RNA, and protein phosphorylation. Proc Natl Acad Sci U S A (1976) 3.24
Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site. Proc Natl Acad Sci U S A (1987) 3.00
Increased rate of degradation of c-myc mRNA in interferon-treated Daudi cells. Proc Natl Acad Sci U S A (1985) 2.35
Intracellular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci U S A (1991) 2.22
Role of the polyadenylate segment in the translation of globin messenger RNA in Xenopus oocytes. Proc Natl Acad Sci U S A (1974) 2.05
Correlation between the antiviral effect of interferon treatment and the inhibition of in vitro mRNA translation in noninfected L cells. J Virol (1973) 2.00
Interferon, double-stranded RNA and mRNA degradation. Nature (1976) 1.70
TAT peptide internalization: seeking the mechanism of entry. Curr Protein Pept Sci (2003) 1.66
Transcriptional and post-transcriptional regulation of c-myc expression during the differentiation of murine erythroleukemia Friend cells. Nucleic Acids Res (1986) 1.62
Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation. Anticancer Drug Des (1993) 1.61
Cloning and characterization of a RNAse L inhibitor. A new component of the interferon-regulated 2-5A pathway. J Biol Chem (1995) 1.60
Discrimination between messenger ribonucleic acids by a mammalian translation initiation factor. Proc Natl Acad Sci U S A (1973) 1.57
Characterization of the messenger ribonucleoprotein released from reticulocyte polyribosomes by EDTA treatment. Eur J Biochem (1971) 1.56
alpha-DNA. VI: Comparative study of alpha- and beta-anomeric oligodeoxyribonucleotides in hybridization to mRNA and in cell free translation inhibition. Nucleic Acids Res (1987) 1.53
Cell-penetrating-peptide-based delivery of oligonucleotides: an overview. Biochem Soc Trans (2007) 1.49
Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol Dis (2008) 1.39
Increased endonuclease activity in an extract from mouse Ehrlich ascites tumor cells which had been treated with a partially purified interferon preparation: dependence of double-stranded RNA;. Biochem Biophys Res Commun (1976) 1.37
Sequence requirements for premature transcription arrest within the first intron of the mouse c-fos gene. Mol Cell Biol (1991) 1.36
Release of messenger RNA from rabbit reticulocyte polyribosomes at low concentration of divalent cations. Biochim Biophys Acta (1967) 1.35
Comparative evaluation of seven oligonucleotide analogues as potential antisense agents. J Med Chem (1993) 1.27
Biological activity of oligonucleotide-poly(L-lysine) conjugates: mechanism of cell uptake. Bioconjug Chem (1991) 1.22
Mechanisms of interferon action: biochemical and genetic approaches. Interferon (1982) 1.22
Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem Soc Trans (2007) 1.17
Interferon, double-stranded RNA and RNA degradation. Characteristics of an endonuclease activity. Eur J Biochem (1977) 1.14
The 2'-5' oligoadenylate/RNase L/RNase L inhibitor pathway regulates both MyoD mRNA stability and muscle cell differentiation. Mol Cell Biol (2000) 1.14
Antiviral activity of conjugates between poly(L-lysine) and synthetic oligodeoxyribonucleotides. Gene (1988) 1.14
Blocks in elongation and initiation of protein synthesis induced by interferon treatment in mouse L cells. Eur J Biochem (1975) 1.13
Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution. AIDS Res Hum Retroviruses (2000) 1.13
Interferon treatment of Ehrlich ascites tumor cells: effects on exogenous mRNA translation and tRNA inactivation in the cell extract. J Virol (1975) 1.11
Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res (1994) 1.10
The 2-5A/RNase L/RNase L inhibitor (RLI) [correction of (RNI)] pathway regulates mitochondrial mRNAs stability in interferon alpha-treated H9 cells. J Biol Chem (2001) 1.10
Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication. Proc Natl Acad Sci U S A (1990) 1.09
Peptide-based delivery of nucleic acids: design, mechanism of uptake and applications to splice-correcting oligonucleotides. Biochem Soc Trans (2007) 1.09
Impairment of reovirus mRNA methylation in extracts of interferon-treated Ehrilich ascites tumor cells: further characteristics of the phenomenon. J Virol (1977) 1.08
Effect of aurintricarboxylic acid and of NaF on the binding of globin messenger RNA to reticulocyte 40S ribosomal subunits. Biochem Biophys Res Commun (1970) 1.07
H19 gene expression is up-regulated exclusively by stabilization of the RNA during muscle cell differentiation. Oncogene (2000) 1.06
Inhibition of reovirus messenger RNA methylation in extracts of interferon-treated Ehrlich ascites tumor cells. Biochem Biophys Res Commun (1975) 1.06
Reversible inhibition of gene expression by a psoralen functionalized triple helix forming oligonucleotide in intact cells. J Biol Chem (1994) 1.04
Mechanism of the interferon-induced block of mRNA translation in mouse L cells: reversal of the block by transfer RNA. FEBS Lett (1974) 1.03
Activation of ribonuclease L by (2'-5')(A)4-poly(L-lysine) conjugates in intact cells. Biochemistry (1986) 1.00
Identification of all HIV type 1 group M subtypes in Senegal, a country with low and stable seroprevalence. AIDS Res Hum Retroviruses (2000) 1.00
Arginine-rich cell penetrating peptides: design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides. J Pept Sci (2008) 1.00
Characterisation of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes. Nucleic Acids Res (1999) 0.98
Interferon treatment inhibits Mengo RNA and haemoglobin mRNA translation in cell-free extracts of L cells. Nat New Biol (1972) 0.97
Antibody targeted liposomes containing poly(rI).poly(rC) exert a specific antiviral and toxic effect on cells primed with interferons alpha/beta or gamma. Biochim Biophys Acta (1989) 0.96
RNase L controls terminal adipocyte differentiation, lipids storage and insulin sensitivity via CHOP10 mRNA regulation. Cell Death Differ (2012) 0.95
Antiviral activity and possible mechanisms of action of oligonucleotides-poly(L-lysine) conjugates targeted to vesicular stomatitis virus mRNA and genomic RNA. Nucleic Acids Res (1989) 0.95
Cell delivery and mechanisms of action of antisense oligonucleotides. Prog Nucleic Acid Res Mol Biol (1993) 0.95
Characterization of the nuclear binding sites of oligodeoxyribonucleotides and their analogs. J Biol Chem (1993) 0.94
Isolation of rabbit reticulocyte 9 S mRNA. Methods Enzymol (1974) 0.93
Translation of mouse interferon mRNA in Xenopus laevis oocytes and in rabbit reticulocyte lysates. Biochem Biophys Res Commun (1978) 0.93
Evidence for a naF-resistant association between mRNA and ribosomes in rabbit reticulocytes. Biochim Biophys Acta (1967) 0.93
Regulation of mitochondrial mRNA stability by RNase L is translation-dependent and controls IFNalpha-induced apoptosis. Cell Death Differ (2007) 0.91
RNase L inhibitor (RLI) antisense constructions block partially the down regulation of the 2-5A/RNase L pathway in encephalomyocarditis-virus-(EMCV)-infected cells. Eur J Biochem (1998) 0.91
Isolation of Daudi cells with reduced sensitivity to interferon. II. On the mechanisms of resistance. J Gen Virol (1983) 0.90
Sequence-specific inhibition of human immunodeficiency virus (HIV) reverse transcription by antisense oligonucleotides: comparative study in cell-free assays and in HIV-infected cells. Proc Natl Acad Sci U S A (1995) 0.89
Antiproliferative effects of antisense oligonucleotides directed to the RNA of c-myc oncogene. Nucleic Acids Res (1991) 0.89
Alpha-DNA.IX: Parallel annealing of alpha-anomeric oligodeoxyribonucleotides to natural mRNA is required for interference in RNase H mediated hydrolysis and reverse transcription. Nucleic Acids Res (1989) 0.89
Structure of globin mRNA and mRNA-protein particles. Use of dark-field electron microscopy. Eur J Biochem (1973) 0.89
Assessment of high-affinity hybridization, RNase H cleavage, and covalent linkage in translation arrest by antisense oligonucleotides. Antisense Nucleic Acid Drug Dev (1998) 0.89
Differential effects of various double-stranded RNAs on protein synthesis in rabbit reticulocyte lysates. Biochemistry (1978) 0.89
Microinjected interferon does not promote an antiviral response in Hela cells. Biochem Biophys Res Commun (1983) 0.88
Mesenger ribonucleoprotein and initiation factors in rabbit-reticulocyte polyribosomes. Eur J Biochem (1973) 0.87
Antisense inhibitors of HIV: problems and perspectives. Antiviral Res (1992) 0.86
Placental BDNF/TrkB signaling system is modulated by fetal growth disturbances in rat and human. Placenta (2010) 0.86
[An association of HIV infection and noma in Niger]. Bull Soc Pathol Exot (2002) 0.85
Poly(L-lysine)-conjugated oligonucleotides promote sequence-specific inhibition of acute HIV-1 infection. Antisense Res Dev (1992) 0.85
Messenger RNA methylation, translation and degradation in extracts of interferon-treated cells. Tex Rep Biol Med (1977) 0.85
Characterization of two murine (2'-5')(A)n-dependent endonucleases of different molecular mass. Eur J Biochem (1989) 0.85
A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy (2008) 0.84
Perinatal undernutrition modifies cell proliferation and brain-derived neurotrophic factor levels during critical time-windows for hypothalamic and hippocampal development in the male rat. J Neuroendocrinol (2009) 0.84
Full-length genome sequencing of HIV type 1 group O viruses isolated from a heterosexual transmission cluster in Senegal. AIDS Res Hum Retroviruses (2001) 0.84
Comparison of interferon action in interferon resistant and sensitive L1210 cells. J Gen Virol (1978) 0.84
Characterization of RNABP, an RNA binding protein that associates with RNase L. J Interferon Cytokine Res (2000) 0.83
Antiviral activity in L1210 cells of liposome-encapsulated (2'-5')oligo(adenylate) analogues. Eur J Biochem (1985) 0.83
Oligonucleotide-poly(L-lysine)-heparin complexes: potent sequence-specific inhibitors of HIV-1 infection. Bioconjug Chem (1994) 0.83
The regulatory strategies of c-myc and c-fos proto-oncogenes share some common mechanisms. Biochimie (1988) 0.83
cDNA cloning and expression analysis of the murine ribonuclease L inhibitor. Gene (1998) 0.83